Alvogen is claiming the first European application for a generic rival to Novartis’ Votrient (pazopanib) oncology treatment, after announcing that it has submitted dossier applications for pazopanib tablets “targeted at several European countries,” implying a use of the EU’s decentralized procedure. No further details of the target markets were revealed.
“Alvogen believes it is the first company going for an approval in the EU,” the company stated, noting that “the pipeline covers both 200mg and 400mg strengths